My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 6 258 / DOI: 10.3332/ecancer.2012.258

Research

HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice

The large amount of literature published over the last two decades on human papillomavirus (HPV)-DNA testing has definitely demonstrated the association between high-risk viral genotypes (hrHPV) and cervical cancer. Moreover, hrHPV-DNA testing has shown excellent performance in several clinical applications, from screening settings to the follow-up of treated patients, compared to conventional cytology or colposcopy options. On the other hand, when a huge number of reports are published on the same subject in a relatively short period of time, with many variations in settings, study designs and applications, the result is often confusion and decreased comprehension by readers. In daily office practice, several different situations (in symptomatic or asymptomatic women) can be positively managed by the correct use of hrHPV-DNA testing. Validated hrHPV-DNA testing and, specifically, the HC2® assay, due to its excellent sensitivity and negative predictive value together with optimal reproducibility, currently represent a powerful tool in the clinician’s hands to optimally manage several situations related to HPV infection and the potential development of cervical cancer.

Loading Article Metrics ... Please wait

Related articles

Case Report: Small cell neuroendocrine tumour of the endometrium and the importance of pathologic diagnosis

Abstract | Full Article | PDF Published: 23 Aug 2016 / DOI: 10.3332/ecancer.2016.668

Review: The role of surgery in advanced epithelial ovarian cancer

Abstract | Full Article | PDF Published: 17 Aug 2016 / DOI: 10.3332/ecancer.2016.666

Conference Report: Highlights from the first International ecancer Conference on Oncology and Radiotherapy, 6–7 May 2016, Santiago, Chile

Abstract | Full Article | PDF | Spanish Published: 22 Jul 2016 / DOI: 10.3332/ecancer.2016.658

Research: The double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screening

Abstract | Full Article | PDF Published: 30 Jun 2016 / DOI: 10.3332/ecancer.2016.650

Clinical Study: Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival

Abstract | Full Article | PDF Published: 03 May 2016 / DOI: 10.3332/ecancer.2016.639



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence